ALK expects to have approved peanut allergy vaccine in 2030

After revealing that it is starting a phase I trial of its peanut allergy vaccine candidate, ALK has now announced that it expects to have an approved vaccine in 2030 at the latest.

Head of Research and Development at ALK, Henrik Jacobi

Head of R&D at ALK Henrik Jacobi thinks the decision to move into peanut allergies makes sense, as the firm already has a lot of experience of developing tablet-based vaccines.

On Monday, the firm revealed that it was starting a phase I study within the indication.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs